Dossier assessment
Emtricitabine/tenofovir alafenamide - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Emtricitabine/tenofovir alafenamide - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Emtricitabine/tenofovir alafenamide - Benefit assessment according to §35a Social Code Book V
Press releases
Emtricitabine/tenofovir alafenamide in HIV infection: added benefit not proven
Deviation from the appropriate comparator therapy / greater harm for certain patients
Additional information
Federal Joint Committee (G-BA)
2016-11-03 A G-BA decision was published.
Project details
- Project no.
- A16-30
- Commission
- Commission awarded on 13.05.2016 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
The current version 1.1 of the dossier assessment replaces version 1.0 published on 15 August 2016.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Addendum
Emtricitabine/tenofovir alafenamide (HIV) - Addendum to Commission A16-30
Status: Commission completed